Our weekly list of news, reports, and information about home health and hospice care. Learn about new studies, trends, CMS regulations and more.
Amedisys, Inc. (NASDAQ: AMED) has entered into a definitive agreement to purchase Asana Hospice for an undisclosed amount. The transaction is expected to close Jan. 1, 2020. Amedisys has been doubling down on hospice acquisitions this year, building up its hospice footprint as the company braces for disruption to its home health care business stemming from the forthcoming transition to the patient-driven groupings model (PDGM). “We are continuing to build and buy in hospice. We continue to work a full hospice tuck-in pipeline while streamlining our internal acquisition integration and absorption process as we wait for industry disruption in home health early next year,” Amedisys CEO Paul Kusserow said in an October earnings conference call. “We will buy opportunistically in home health once we see what PDGM looks like and build networks to expand our personal care coverage.”
Hospices will soon have the opportunity to participate in value-based payment models such as Medicare Advantage and Primary Care First. To be successful in such an environment, providers need to strengthen their skillsets when it comes to early patient identification, population stratification, among other competencies. Medicare Advantage plans are offered by private insurance companies approved by the U.S. Centers for Medicare & Medicaid Services (CMS), and include HMO, PPO, and fee-for-service plans among other options. The program represents an integrated care model that promotes coordination of services and provides incentives for quality and patient satisfaction. Beginning in 2020, the program will be available in all 50 states as well as U.S. territories. CMS earlier this year announced that it would test coverage of hospice care through Medicare Advantage plans beginning in 2021. The carve-in, according to CMS, is intended to increase access to hospice services and facilitate better coordination between patients’ hospice providers and their other clinicians.
A month has gone by since the last earnings report for Amedisys (AMED). Shares have added about 24.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Amedisys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Top Estimates Amedisys reported adjusted earnings per share of $1.15 in the third quarter of 2019, up 21.1% from the year-ago figure. The bottom line also beat the Zacks Consensus Estimate of 97 cents by 27.8%. Net service revenues grossed $494.6 million, up 18.5% year over year. Meanwhile, the top line marginally matched the Zacks Consensus Estimate.
Palliative Care Market SWOT Analysis and innovations by Leading Key Players Kindred Healthcare, Gentiva Health
HTF MI Analyst have added a new research study on Title Global Palliative Care Market Size, Status and Forecast 2019-2025 with detailed information of Product Types, Private Residence Care, Hospice Inpatient Care, Hospital Inpatient Care, Nursing Home and Residential Facility Care & Others, Applications [Hospitals, Home Care Settings, Palliative Care Centers, Long-Term Care Centers & Rehabilitation Centers & Others] & Key Players such as Vitas Healthcare, Skilled Healthcare Group, Sunrise Senior Living, Kindred Healthcare, Gentiva Health, Home Instead Senior, Amedisys & Genesis HealthCare etc.